Own CSL shares? Here's what to watch in next week's earnings update

This blue chip is releasing its eagerly anticipated results next week. Here's what to expect.

| More on:
Health professional working on his laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares will be closely watched by Aussie investors next week.

That's because the biotechnology giant is scheduled to release its half year results on Tuesday 11 February.

Ahead of the release, let's take a look at what the market is expecting from the popular ASX 200 blue chip share.

CSL half year results preview

According to a note out of Goldman Sachs, its analysts are expecting the company to deliver a half year result that is a touch ahead of the market's expectations.

Goldman is forecasting total revenue of US$8,663 million for the six months ended 31 December. This is 1.3% ahead of the consensus estimate.

This is expected to be driven by CSL Behring sales of US$5,739 million (+0.7% vs consensus), CSL Seqirus sales of US$1,852 million (+0.7% vs consensus), and CSL Vifor sales of US$1,072 million (5.6% vs consensus).

In respect to the key CSL Behring business, Goldman believes that better that consensus immunoglobulins and albumin sales will help the company outperform the market's expectations.

And with Goldman forecasting a better than expected EBIT margin of 34.8%, it believes that CSL's earnings will also come in ahead of consensus estimates.

The broker is forecasting half year underlying EBIT of US$3,017 million (+1.7% vs consensus) and NPATA of US$2,270 million (+2.2% vs consensus).

Should you buy CSL shares?

Given its positive view on the company's performance and its belief that CSL's shares are being undervalued by the market, it will come as little surprise to learn that Goldman Sachs is bullish on the investment opportunity here.

The broker currently has a buy rating and $325.40 price target on the company's shares.

Based on the current CSL share price of $271.94, this implies potential upside of almost 20% for investors over the next 12 months.

Commenting on its buy recommendation, Goldman Sachs said:

Our Buy recommendation for CSL is driven by (1) Strong growth in the IG market despite the entry of new drugs (anti-FcRn), (2) CSL market share gains in the IG market, Hemophilia, Hereditary Angiodema (HAE) and influenza vaccines, and (3) Gross Margin accretion driven by operational improvements to its cost base. We believe CSL's valuation multiple de-rate is onerous considering the growth outlook, particularly for IG therapies.

Key risks include: (1) US inflation impacting plasma donor fees, (2) Successful launch of human recombinant albumin in China, and (3) IG market share loss from launch of new therapies.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Two smiling work colleagues discuss an investment or business plan at their office.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Market News

Here's how the ASX 200 market sectors stacked up last week

ASX 200 technology stocks led the market with a 1.99% rise while the benchmark index slipped 0.24%.

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 30% to 40%

Analysts are tipping these shares to generate big returns over the next 12 months.

Read more »

A female worker in a hard hat smiles in an oil field.
Broker Notes

Buy BHP and this ASX 200 share next week

Here are a couple of shares that Bell Potter rate highly this month.

Read more »

Legendary share market investing expert and owner of Berkshire Hathaway Warren Buffett
Share Market News

I'd listen to Warren Buffett and invest in ASX shares with wide economic moats

It could pay to follow in the footsteps of Warren Buffett. Here's what you need to know about moats.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Best Shares

Top oversold ASX shares to buy in February 2025

Hoping to bag an investment bargain this month?

Read more »

People sit in rollercoaster seats with expressions of fear, terror and exhilaration as it goes into a steep downward descent representing the Novonix share price in FY22
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough end to the trading week this Friday.

Read more »

A panel of four judges hold up cards all showing the perfect score of ten out of ten
52-Week Highs

Big ASX news: 10 ASX 200 shares hit new 52-week highs today

Do you own any of these lucky stocks?

Read more »